2026-08-12T10:51:46-05:00 2025-12-31 510229493 BARBACANE THORNTON & COMPANY LLP 593 CARR ROAD SUITE 100 WILMINGTON DE 19809 990 2025-01-01 383569922 NEPHCURE KIDNEY INTERNATIONAL NEPH 8666374287 5 CENTER AVENUE SUITE D COLLEGEVILLE PA 19426 MICHAEL LEVINE PRESIDENT 8666374287 2026-08-12 JEFFREY A KOWALCZYK CPA P01563311 3024788940 2026-08-05 2025 2025-03-06 01:10:19Z MICHAEL LEVINE 5 CENTER AVENUE SUITE D COLLEGEVILLE PA 19426 7325906 0 X WWW.NEPHCURE.ORG X 2000 MI NEPHCURE KIDNEY INTERNATIONAL IS THE ONLY ORGANIZATION COMMITTED EXCLUSIVELY TO SUPPORTING RESEARCH SEEKING THE CAUSE OF THE POTENTIALLY DEBILITATING KIDNEY DISEASE OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) AND NEPHROTIC SYNDROME. THE ORGANIZATION IS COMMITTED TO IMPROVING TREATMENT AND FINDING A CURE FOR THIS DISEASE. 26 26 27 440 0 0 5393306 6678987 0 0 0 0 208556 78614 5601862 6757601 66250 16245 0 0 2620675 2944803 0 0 592314 3186040 3203543 5872965 6164591 -271103 593010 3897873 4358213 880264 600413 3017609 3757800 X NEPHCURE KIDNEY INTERNATIONAL IS THE ONLY ORGANIZATION COMMITTED EXCLUSIVELY TO SUPPORTING RESEARCH SEEKING THE CAUSE OF THE POTENTIALLY DEBILITATING KIDNEY DISEASE OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) AND NEPHROTIC SYNDROME. THE ORGANIZATION IS COMMITTED TO IMPROVING TREATMENT AND FINDING A CURE FOR THIS DISEASE. 0 0 2219150 16245 RESEARCH - NEPHCURE KIDNEY INTERNATIONAL IS COMMITTED TO MULTI-YEAR GRANTS FOR BASIC, TRANSLATIONAL, AND CLINICAL SCIENTIFIC RESEARCH. THE PURPOSE OF THIS RESEARCH IS TO DETERMINE CAUSES OF KIDNEY DISEASE, FSGS & NEPHROTIC SYNDROME THAT COULD LEAD TO EFFECTIVE TREATMENTSCLINICAL TRIAL SUPPORT - NEPHCURE KIDNEY INTERNATIONAL SUPPORTSAND FACILITATES CLINICAL RESEARCH BY ACTIVELY SUPPORTING PATIENT RECRUITMENT TO ADDRESS THE GROWING DEMAND OF CLINICAL TRIALS. 2942168 HEALTH AND EDUCATION - NEPHCURE KIDNEY INTERNATIONAL FUNDS AND MANAGES PROGRAMS TO EDUCATE PATIENTS/FAMILIES ABOUT NEPHROTIC SYNDROME & FSGS. NEPHCURE KIDNEY INTERNATIONAL ALSO PROVIDES EDUCATION MATERIALS (BI-LINGUAL) FOR PHYSICIANS AND DIRECTLY TO PATIENT FAMILIES. 5161318 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 43 0 27 1 0 1 CA 0 0 0 0 0 0 0 0 0 0 X 26 26 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT FL GA KS KY IL LA ME MD MA MI MN MS MO NH NJ NM NY NC OK OH OR PA RI SC TN UT VA WV WA WI X THE ORGANIZATION 8666374287 5 CENTER AVENUE SUITE D COLLEGEVILLE PA 19426 IRVING SMOKLER BOARD CHAIRMAN 5.00 X X 0 0 0 CHRIS WHITNEY VICE PRESIDENT 1.00 X X 0 0 0 ANDREW SILVERMAN TREASURER 3.00 X X 0 0 0 MICHAEL LEVINE PRESIDENT 5.00 X X 0 0 0 CAROL SMOKLER SECRETARY 1.00 X X 0 0 0 ELAINE KAMIL MEMBER 1.00 X 0 0 0 DAVID KERSHAW MEMBER 1.00 X 0 0 0 WILLIAM SMOYER MEMBER 1.00 X 0 0 0 KIRK CAMPBELL MEMBER 1.00 X 0 0 0 CHARLES DAVIS III MEMBER 1.00 X 0 0 0 CHRISTOPHER WINDISCH MEMBER 1.00 X 0 0 0 JENNIFER GEISSER MEMBER 1.00 X 0 0 0 JIM DUQUETTE MEMBER 1.00 X 0 0 0 JOSHUA ROY MEMBER 1.00 X 0 0 0 KEVIN MOTT MEMBER 1.00 X 0 0 0 LEROY MILES MEMBER 1.00 X 0 0 0 LAUREL DAMASHEK MEMBER 1.00 X 0 0 0 MANU VARMA MEMBER 1.00 X 0 0 0 MARTIN ZIMMERMAN MEMBER 1.00 X 0 0 0 REBECCA OAG MEMBER 1.00 X 0 0 0 SARRETTA MCDONOUGH MEMBER 1.00 X 0 0 0 STEPHEN HOLLOMON MEMBER 1.00 X 0 0 0 TROY JONES MEMBER 1.00 X 0 0 0 SCOTT GOLDSTEIN MEMBER 1.00 X 0 0 0 TYLER WELLMAN MEMBER 1.00 X 0 0 0 BARBARA GILLESPIE MEMBER 1.00 X 0 0 0 JOSH TARNOFF CHIEF EXECUTIVE OFFICER 40.00 X 309624 0 14260 REBECCA COOK DIRECTOR, STRATEGIC OPERATIONS 40.00 X 152214 0 17007 LAUREN EVA EXECUTIVE VP, COO 40.00 X 199999 0 38257 SUSAN SIKORA BRISENDINE VP, DEVELOPMENT & INNOVATION 40.00 X 214375 0 43930 BRITTA DORNAN EX DIR, STRATEGIC RELATIONS 40.00 X 150403 0 6803 KYLIE KARLEY DIRECTOR, MARKETING COMMUNICATION 40.00 X 119712 0 27442 1146327 0 147699 7 0 1 0 0 1269443 5409544 12462 6678987 78614 0 78614 78614 78614 568305 1269443 568305 0 6757601 0 0 78614 16245 16245 323884 275302 3239 45343 1945470 1817687 21703 106080 54040 24105 284 29651 458883 204691 2407 251785 162526 151851 1813 8862 582702 320486 221426 40790 407250 230863 134217 42170 342406 291045 17120 34241 215620 176808 6469 32343 83676 83676 CLINICAL MODELING PROJE 762928 762928 PATIENT EDUCATION 536612 536612 HEALTH EQUITY 204044 204044 RESEARCH PAYMENTS 63744 63744 4561 1231 2281 1049 6164591 5161318 410959 592314 3597061 3701243 97489 480979 69896 175991 133427 0 3897873 4358213 789144 600413 91120 0 880264 600413 X 3016619 3682232 990 75568 3017609 3757800 3897873 4358213 593010 147181 0 X X 0 1 X 1 0 X 3910926 4495178 4200803 5393306 6678987 24679200 3910926 4495178 4200803 5393306 6678987 24679200 24679200 24679200 1.00000 1.00000 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 1 1 1 0 35000 1 0 0 X 6904782 147181 147181 6757601 0 6757601 6164591 0 6164591 0 6164591 PART X, LINE 2: NEPHCURE KIDNEY INTERNATIONAL IS EXEMPT FROM FEDERAL INCOME TAX UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. HOWEVER, INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO THE ORGANIZATION'S TAX-EXEMPT PURPOSE MAY BE SUBJECT TO TAXATION AS UNRELATED BUSINESS INCOME. GENERALLY ACCEPTED ACCOUNTING PRINCIPLES PRESCRIBE RULES FOR THE RECOGNITION, MEASUREMENT, CLASSIFICATION, AND DISCLOSURE IN THE FINANCIAL STATEMENTS OF UNCERTAIN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN THE ORGANIZATION'S TAX RETURNS. MANAGEMENT HAS DETERMINED THAT THE ORGANIZATION DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS OR ASSOCIATED UNRECOGNIZED BENEFITS THAT MATERIALLY IMPACT THE FINANCIAL STATEMENTS OR RELATED DISCLOSURES. SINCE TAX MATTERS ARE SUBJECT TO SOME DEGREE OF UNCERTAINTY, THERE CAN BE NO ASSURANCE THAT THE ORGANIZATION'S TAX RETURNS WILL NOT BE CHALLENGED BY THE TAXING AUTHORITIES AND THAT THE ORGANIZATION WILL NOT BE SUBJECT TO ADDITIONAL TAX, PENALTIES, AND INTEREST AS A RESULT OF SUCH CHALLENGE. CDTAC NY 735440 421289 314151 314151 ALL IN FOR A CURE 275841 144442 131399 131399 8 826467 703712 122755 122755 1837748 1269443 568305 568305 568305 0 1 UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 200 E CAMERON AVENUE CHAPEL HILL NC 27514 566001393 16245 0 RESEARCH GRANT X X 0 0 0 0 0 0 0 0 0 JOSH TARNOFF CHIEF EXECUTIVE OFFICER 309624 0 0 0 0 0 0 0 14260 0 323884 0 0 0 SUSAN SIKORA BRISENDINE VP, DEVELOPMENT & INNOVATION 214375 0 0 0 0 0 0 0 43930 0 258305 0 0 0 LAUREN EVA EXECUTIVE VP, COO 199999 0 0 0 0 0 0 0 38257 0 238256 0 0 0 REBECCA COOK DIRECTOR, STRATEGIC OPERATIONS 152214 0 0 0 0 0 0 0 17007 0 169221 0 0 0 BRITTA DORNAN EX DIR, STRATEGIC RELATIONS 150403 0 0 0 0 0 0 0 6803 0 157206 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 TWO BOARD MEMBERS ARE RELATED BY MARRIAGE FORM 990, PART VI, SECTION B, LINE 11B A FINAL COPY OF FORM 990 IS PROVIDED TO EACH VOTING MEMBER OF THE GOVERNING BOARD. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD REVIEWS COMPLETED CONFLICT OF INTEREST QUESTIONNAIRES AND DISCLOSES INFORMATION DURING THE ANNUAL BOARD MEETING FOR BOARD APPROVAL. FORM 990, PART VI, SECTION B, LINE 15 CEO AND OTHER EMPLOYEE COMPENSATION IS EVAUATED AND APPROVED BY THE BOARD OF DIRECTORS, UTILIZING COMPARABLITY DATA AND OTHER INPUTS. FORM 990, PART VI, SECTION C, LINE 19 990 AVAILABLE UPON REQUEST. PART XII LINE 2C THE PROCESS HAS NOT CHANGED FROM PRIOR YEAR